Medicinal Products

Volqer 200 mg tablete s produljenim oslobađanjem

Name Volqer 200 mg tablete s produljenim oslobađanjem
Marketing Authorisation Number HR-H-866394670
Active Substance quetiapinum
Pharmaceutical Form tableta s produljenim oslobađanjem
Strength 200 mg
Packaging [MA Number for Packaging] 10 tableta u blisteru, u kutiji  [HR-H-866394670-01]
30 tableta u blisteru, u kutiji  [HR-H-866394670-02]
50 tableta u blisteru, u kutiji  [HR-H-866394670-03]
56 tableta u blisteru, u kutiji  [HR-H-866394670-04]
60 tableta u blisteru, u kutiji  [HR-H-866394670-05]
100 tableta u blisteru, u kutiji  [HR-H-866394670-06]
60 tableta u bočici, u kutiji  [HR-H-866394670-07]
120 tableta u bočici, u kutiji  [HR-H-866394670-08]
Manufacturer Salutas Pharma GmbH, Barleben, Njemačka;
Pharmathen International S.A., Rodopi, Grčka;
Pharmathen S.A., Pallini Attikis, Atena, Grčka
Marketing Authorisation Holder Sandoz d.o.o., Maksimirska 120, Zagreb
Marketing Authorisation Date 30.10.2015
MA Period of Validity 30.10.2020
MA Revocation Date 18.02.2019*
Classification Number UP/I-530-09/15-01/146
Registration Number 381-12-01/70-15-05
Composition jedna tableta s produljenim oslobađanjem sadrži 200 mg kvetiapina (u obliku kvetiapinfumarata)
Prescription na recept
Type of prescription ponovljivi recept
Distribution u ljekarni
Advertising to general public zabranjeno
ATC Code N05AH04
Medicinal product marketed in the Croatia Trajni prekid opskrbe
SmPC download
PL download
Public Assessment Report download
Educational materials
for healthcare professionals
Podsjetnik o važnosti nadziranja metaboličkih parametara tijekom liječenja kvetiapinom, verzija 2


Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act (Official Gazette No. 76/13), only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.